COPENHAGEN (Reuters) – Danish drug developer Novo Nordisk on Thursday reported first-quarter operating profit above analyst forecasts, helped by sales in the United States of its hugely popular Wegovy weight-loss drug.
Novo reported earnings before interest and taxes (EBIT) of 25 billion Danish crowns ($3.72 billion), above an average analyst forecast of 22.4 billion, according to a Refinitiv poll.
($1 = 6.7221 Danish crowns)
(Reporting by Nikolaj Skydsgaard, editing by Terje Solsvik)
